Ambulatory treatment of acute myeloid leukemia (AML) with weekly oral idarubicin alone in poor-risk elderly patients.

被引：0
|
作者：
Anglaret, B
Belhabri, A
Chelghoum, Y
Renaudier, P
Troncy, J
Bouheddou, N
Peaud, PY
Chevalier, MP
Thomas, X
机构：
[1] Ctr Hosp, Valence, France
[2] Hop Edouard Herriot, Lyon, France
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4621
引用
收藏
页码：208B / 208B
页数：1
相关论文
共 50 条
  • [31] Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia
    Allen, Steven L.
    Kolitz, Jonathan E.
    Lundberg, Ante S.
    Bennett, John M.
    Capizzi, Robert L.
    Budman, Daniel R.
    LEUKEMIA RESEARCH, 2010, 34 (04) : 487 - 491
  • [32] MDR1 gene expression in poor-risk Acute Myeloid Leukemia (AML) with partial or complete monosomy 7.
    van den Heuvel-Eibrink, MM
    Wiemer, E
    de Boevere, MJ
    Smit, E
    Schoester, M
    Slater, R
    van Noesel, MM
    van der Holt, B
    Pieters, R
    Sonneveld, P
    LEUKEMIA, 2001, 15 (03) : 501 - 501
  • [33] THE EFFECT OF DECREASED-DOSE IDARUBICIN FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Ichikawa, M.
    Kobayashi, T.
    Nannya, Y.
    Kurokawa, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 108 - 108
  • [34] Induction chemotherapy with high-dose cytarabine and mitoxantrone in elderly acute myeloid leukemia (AML) patients.
    Ramanathan, Muthalagu
    Cerny, Jan
    Raffel, Glen
    Walsh, William Vincent
    Woda, Bruce
    Miron, Patricia
    Nath, Rajneesh
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] ORAL IDARUBICIN IN THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA AND THE BLAST PHASE OF CHRONIC MYELOID-LEUKEMIA
    MALIK, STA
    TUCKER, J
    ROHATINER, AZS
    BRACE, W
    LISTER, TA
    HEMATOLOGICAL ONCOLOGY, 1989, 7 (06) : 423 - 427
  • [36] Mutational Signature Correlates with Proliferative Phenotype in NCCN Poor-Risk Acute Myeloid Leukemia
    Shaver, Aaron C.
    Juskevictus, Ridas
    Dabei, Robert D.
    Strickland, Stephen A.
    Ferrell, Paul B.
    Byrne, Michael
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Mary M.
    Kim, Annette S.
    Seegmiller, Adam
    Savona, Michael R.
    Head, David R.
    LABORATORY INVESTIGATION, 2017, 97 : 377A - 377A
  • [37] GENTUZUMAB-OZOGAMICIN (GO) PLUS IDARLIBICIN (I) AND CYTARABINE (C) AS INDUCTION TREATMENT FOR ELDERLY PATIENTS WITH POOR-RISK CYTOGENETICS ACUTE MYELOID LEUKEMIA (AML), RESULTS OF GOELAMS LAMR04 STUDY
    Delaunay, J.
    Recher, C.
    Vey, N.
    Witz, E.
    Lioure, B.
    Tournilhac, O.
    Himberlin, C.
    Bouscary, D.
    Ifrah, N.
    Harousseau, J. L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 17 - 17
  • [38] Mutational Signature Correlates with Proliferative Phenotype in NCCN Poor-Risk Acute Myeloid Leukemia
    Shaver, Aaron C.
    Juskevicius, Ridas
    Dabei, Robert D.
    Strickland, Stephen A.
    Ferrell, Paul B.
    Byrne, Michael
    Mohan, Sanjay R.
    Vnencak-Jones, Cindy L.
    Zutter, Maly M.
    Kim, Annette S.
    Seegmiller, Adam
    Savona, Michael R.
    Head, David R.
    MODERN PATHOLOGY, 2017, 30 : 377A - 377A
  • [39] The Treatment of Elderly Patients With Acute Myeloid Leukemia
    Krug, Utz
    Buechner, Thomas
    Berdel, Wolfgang E.
    Mueller-Tidow, Carsten
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (51-52): : 863 - U11
  • [40] Treatment of Elderly Patients With Acute Myeloid Leukemia
    Xavier Thomas
    Caroline Le Jeune
    Current Treatment Options in Oncology, 2017, 18
12345